Agilyx ASA reports Q3 results (OTCMKTS:AGXXF)

Agilyx ASA reported Q3 2026 results: EUR 84 million revenue, EUR 3.6 million EBITDA, and EUR 27.5 million cash. The company is listed on OTCMKTS under the ticker AGXXF.

Original reporting
Published Nov 10, 2026, 10:57 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 11:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$AGXXF
Neutral
medium confidence
Mentioned
$AGXXF
Relevance
6/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$AGXXFNeutralMed
01

Why it matters

The Q3 release adds the first publicly available financial details for the quarter, enabling valuation updates.

02

Market read

Provides fresh data for a micro‑cap energy firm; limited broader market impact.

03

What to watch

Cash balance of €27.5 million provides runway for future projects despite low earnings.

Relevance 6/10Novelty 8/10Timing: after-hours

Background

Agilyx ASA is a Norwegian waste‑to‑energy company listed on the OTC market.

Company-level read

Ticker impact

$AGXXFNeutralMedium confidence
Context

Q3 results disclosed: €84 million revenue, €3.6 million EBITDA, €27.5 million cash.

Expected impact

potential modest downside if results fall short of market expectations

Evidence & confidence

Small-cap foreign issuer; numbers are modest and likely already priced in, but new data may trigger short‑term moves.

Market effects

Limited impact on broader waste‑to‑energy sector; results may inform peer comparisons.

Minor effect on Nordic renewable‑energy equities.

Low

Counterpoint

Investors could view the modest EBITDA as a sign of operational efficiency and consider a long position.

Key entities

  • Agilyx ASA

    Norwegian waste‑to‑energy firm reporting Q3 2026 results.

Related articles

$INOHighAI 8/10

Inovio Q3 2026 slides: VOCERYQ approval amid wider loss

Inovio Pharmaceuticals reported a Q3 2026 net loss of $49.2M, wider than expected, despite FDA approval of VOCERYQ. Shares fell 3.97% to $1.45, then another 10.34% after hours. Operating expenses declined 7% YoY, but non-cash losses increased. Cash reserves total $48.4M, with a runway into late 2027. VOCERYQ targets recurrent respiratory papillomatosis, showing 50-100% surgery reduction in trials. The company plans a Q1 2027 launch and European filings by year-end.

$EMBJHighAI 8/10

Embraer (EMBJ) Q3 2026 Earnings Call Transcript

Embraer (EMBJ) reported Q3 2026 earnings with a 17% revenue increase to $2.35B and adjusted EBIT margin of 10.9%. Backlog reached $35.7B, up 14% YoY. Commercial Aviation revenue rose 13% to $696M, while Executive Aviation and Defense & Security also saw growth. The company raised revenue guidance to $8.4B-$8.6B and increased adjusted free cash flow guidance to $700M+.

$RDNWMed

What RideNow Group (RDNW) Said on Its Q3 Earnings Call

RideNow Group (RDNW) reported Q3 sales declines, with new and pre-owned unit sales down 11.3% and 10% YoY, respectively. Margins were pressured by lower-margin products and inventory challenges. The company cut costs and refinanced debt, ending Q3 with $47.6M in cash and $149.4M in liquidity. Management expects further cost savings and inventory normalization by Q1 2024.

$SONOMed

Sonos Q4 Earnings Call Highlights

Sonos reported Q4 GAAP gross margin of 46.1%, aided by $18M in tariff refunds. Inventory rose 60% YoY to $273M. For Q1 FY2027, revenue is forecasted at $570M-$630M, with GAAP gross margin expected at 36%-37%. Memory costs and a stronger dollar are pressuring margins. Sonos introduced five new products and has an installed base of 17.7M households. The company completed $130M in share repurchases and has a new $150M authorization.